600521 Zhejiang Huahai Pharmaceutical
- 17.69
- +0.30+1.73%
Zhejiang Huahai Pharmaceutical News
Huahai Pharmaceutical's Unit Gets Nod to Register Atomoxetine Hydrochloride Oral Solution
Zhejiang Huahai Pharmaceutical's (SHA:600521) unit, Changxing Pharmaceutical, received a drug registration certificate from China's National Medical Products Administration for its atomoxetine hydroch
Is Zhejiang Huahai Pharmaceutical Co., Ltd.'s (SHSE:600521) Recent Stock Performance Tethered To Its Strong Fundamentals?
Zhejiang Huahai Pharmaceutical (SHSE:600521) has had a great run on the share market with its stock up by a significant 47% over the last three months. Since the market usually pay for a company's l
Huahai Pharmaceutical's Q1 Profit Jumps 57%, Income Up 21%
Zhejiang Huahai Pharmaceutical (SHA:600521) booked a net profit attributable to shareholders of 270.8 million yuan in the first quarter of the year, jumping 56.6% from 172.9 million yuan a year earlie
Huahai Pharmaceutical (600521.SH): Controlling shareholder and actual controller Chen Baohua increased his total holdings of the company by 3.18 million shares
Gelonghui, April 30 | Huahai Pharmaceutical (600521.SH) announced that as of the disclosure date of this announcement, Mr. Chen Baohua, the controlling shareholder and actual controller of the company, had increased his holdings of the Company's shares by 3.18 million shares through centralized bidding transactions at the Shanghai Stock Exchange, accounting for 0.21% of the company's total share capital. The total amount of increase in holdings was 49,518,278 yuan. The actual amount of Mr. Chen Baohua's holdings increase this time has exceeded the lower limit of the range of the holdings increase plan, and the implementation period for the increase in holdings has expired, and the implementation of the current holdings increase plan has been completed.
Huahai Pharmaceutical Gets Approval to Market Busulfan Injection
Zhejiang Huahai Pharmaceutical (SHA:600521) received a drug registration certificate from China's National Medical Products Administration for its busulfan injection, according to the company's disclo
Huahai Pharmaceutical (600521.SH): Busulan injection obtained a drug registration certificate
Gelonghui, April 23 | Huahai Pharmaceutical (600521.SH) announced that the company recently received the “Drug Registration Certificate” for the Bexuan injection approved and issued by the State Drug Administration. Busulinan injection is suitable for use with cyclophosphamide as a pretreatment plan for hematopoietic progenitor cells of chronic myeloid leukemia before transplantation.
Huahai Pharmaceutical (600521.SH) completed the repurchase of 7.023,600 shares at a cost of about 100 million yuan
Huahai Pharmaceutical (600521.SH) announced that on April 17, 2024, the company completed the repurchase and actually repurchased the public...
Investors Continue Waiting On Sidelines For Zhejiang Huahai Pharmaceutical Co., Ltd. (SHSE:600521)
It's not a stretch to say that Zhejiang Huahai Pharmaceutical Co., Ltd.'s (SHSE:600521) price-to-earnings (or "P/E") ratio of 27x right now seems quite "middle-of-the-road" compared to the market in
Zhejiang Huahai Pharmaceutical Gets Chinese Registration Nod for Torsemide Tablets
Zhejiang Huahai Pharmaceutical (SHA:600521) obtained drug registration approval from China's medical products association for its torsemide tablets, according to a Wednesday filing with the Shanghai b
Zhejiang Huahai Pharmaceutical Forecasts Up to 65% Rise in Q1 Profit
Zhejiang Huahai Pharmaceutical (SHA:600521) forecasts its attributable profit to increase 50% to 65% to between 259.5 million yuan and 285.5 million yuan in the first quarter from 172.9 million yuan i
Shyndec Pharmaceutical's Unit Gets Nod to Register Empagliflozin Tablets
Zhejiang Huahai Pharmaceutical (SHA:600521) obtained a drug registration certificate from China's National Medical Products Administration for its empagliflozin tablets, according to the company's fil
Huahai Pharmaceutical (600521.SH) obtained torasemide tablet drug registration certificate
Huahai Pharmaceutical (600521.SH) issued an announcement. The company recently received approval and issuance from the State Drug Administration...
Huahai Pharmaceutical (600521.SH): Empagliflozin tablets obtained drug registration certificate
Gelonghui, April 15, 丨 Huahai Pharmaceutical (600521.SH) announced that it has recently received the “Drug Registration Certificate” for englicin tablets approved and issued by the State Drug Administration. Engagliptin tablets are used to treat adult patients with type 2 diabetes and heart failure.
Huahai Pharmaceutical (600521.SH): Net profit for the first quarter is expected to increase by about 50% to 65% year-on-year
Gelonghui, April 15 | Huahai Pharmaceutical (600521.SH) announced that according to preliminary estimates by the financial department, the company's net profit attributable to shareholders of listed companies in the first quarter of 2024 is expected to be between RMB 259.5 million and RMB 285.5 million. Compared with the same period last year (statutory disclosure data), it will increase by about RMB 86.57 million to RMB 112.57 million, an increase of about 50% to 65% over the previous year. The company's net profit for the first quarter of 2024, which is attributable to shareholders of listed companies after deducting non-recurring profit and loss, is expected to be between RMB 292.2 million and RMB 320.5 million, the same period as the previous year (statutory disclosure
Huahai Pharmaceutical (600521.SH)'s application to issue shares to specific targets was approved by the Securities Regulatory Commission for registration approval
Huahai Pharmaceutical (600521.SH) issued an announcement. The company received an announcement from the China Securities Regulatory Commission on April 2, 2024...
Huahai Pharmaceutical (600521.SH) has spent 99.9851 million yuan to buy back 7.023,300 shares
Huahai Pharmaceutical (600521.SH) issued an announcement. As of March 31, 2024, the company has made a total number of repurchases...
Earnings Are Growing at Zhejiang Huahai Pharmaceutical (SHSE:600521) but Shareholders Still Don't Like Its Prospects
As an investor its worth striving to ensure your overall portfolio beats the market average. But if you try your hand at stock picking, your risk returning less than the market. Unfortunately, that'
Huahai Pharmaceutical (600521.SH): Torasemide injection obtained drug registration certificate
Huahai Pharmaceutical (600521.SH) announced that the company recently received the approval and issuance of Torasepam by the State Drug Administration...
Changxing Pharmaceutical, a subsidiary of Huahai Pharmaceutical (600521.SH), increased 10.74% year-on-year in 2023 net profit of 669.17,400 yuan
Huahai Pharmaceutical (600521.SH) issued an announcement stating that the company's holding subsidiary Changxing Pharmaceutical Co., Ltd. (abbreviation “...
Huahai Pharmaceutical (600521.SH) has repurchased a total of 7.023,300 shares at a cost of 99.9851 million yuan
Huahai Pharmaceutical (600521.SH) issued an announcement. As of February 29, 2024, the company has made a total number of repurchases...
Analysis
Price Target
No Data
